Key Product Details

Species Reactivity

Validated:

Human, Mouse

Cited:

Human, Mouse

Applications

Validated:

ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot

Cited:

Dot Blot, Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG1 kappa Clone # 5C2

Format

BSA Free

Concentration

1.0 mg/ml

View all alpha-Synuclein Antibodies »

Product Specifications

Immunogen

This alpha-Synuclein Antibody (5C2) was developed against recombinant human alpha-synuclein (61-95) purified from E. coli (NP_0003360).

Reactivity Notes

Use in Mouse reported in scientific literature (PMID:30918024).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG1 kappa

Theoretical MW

14.46 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for alpha-Synuclein Antibody (5C2) - BSA Free

Western Blot: alpha-Synuclein Antibody (5C2)BSA Free [NBP1-04321]

Western Blot: alpha-Synuclein Antibody (5C2)BSA Free [NBP1-04321]

Western Blot: alpha-Synuclein Antibody (5C2) [NBP1-04321] - The recombinant human alpha-synuclein domains were resolved by SDS-PAGE, transferred to PVDF membrane and probed with human anti-alpha-Synuclein(61-95aa) antibody (1:1000). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.Lane 1.: Recombinant human alpha-synuclein(1-60aa)Lane 2.: Recombinant human alpha-synuclein(1-95aa)Lane 3.: Recombinant human alpha-synuclein(61-140aa)Lane 4.: Recombinant human alpha-synuclein(96-140aa)
Western Blot: alpha-Synuclein Antibody (5C2)BSA Free [NBP1-04321]

Western Blot: alpha-Synuclein Antibody (5C2)BSA Free [NBP1-04321]

Western Blot: alpha-Synuclein Antibody (5C2) [NBP1-04321] - The recombinant human synuclein family proteins were resolved by SDS-PAGE, transferred to PVDF membrane and probed with human anti-alpha-Synuclein antibody (1:1000). Proteins were visualized using a goat anti-mouse secondary antibody conjugated to HRP and an ECL detection system.Lane 1.: Recombinant human alpha-synucleinLane 2.: Recombinant human beta-synucleinLane 3.: Recombinant human gamma-synuclein

Applications for alpha-Synuclein Antibody (5C2) - BSA Free

Application
Recommended Usage

ELISA

1:100-1:2000

Western Blot

1:500-1:2000

Reviewed Applications

Read 1 review rated 3 using NBP1-04321 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

PBS (pH 7.4), 10% Glycerol

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: alpha-Synuclein

Alpha-synuclein, a member of the synuclein family, is a protein that was first identified in 1988 whose name is derived from its localization to both the synapse and nucleus (1-3). Specifically, it is expressed primarily in the brain, including Lewy Bodies (1-6). Alpha-synuclein is encoded by the SNCA gene, located on chromosome 4p21, and is processed as a 140 amino acid (aa) protein with a theoretical molecular weight of 14 kDa (1,2,4). Structurally alpha-synuclein consists of a N-terminal binding domain (1-60 aa), a central domain core region called the non-amyloid-beta component (NAC) (61-95 aa), and a C-terminal domain (96-140 aa) (1-3). The N-terminal region contains aa repeats with a KTKEGV consensus sequence that gives the protein its alpha-helical structure that associates with lipid membranes (1-4). The hydrophobic NAC region is responsible for alpha-synuclein aggregation and fibril formation (1-4). The acidic C-terminal tail is largely unstructured but can be targeted for post-translational modifications (1-4). The function of alpha-synuclein is not entirely understood, but it is shown to have a role in suppression of apoptosis, acting as a molecular chaperone, regulating glucose, and modulating calmodulin activity (1,3).

A number of studies have revealed that alpha-synuclein aggregation is a hallmark feature in a number of neurodegenerative diseases, referred to as synucleinopathies (2-4). Alpha-synuclein protein aggregates are a large component of Lewy bodies that are present in Parkinson's disease (PD), Lewy body dementia (LBD), and multiple system atrophy (1-6). Research has shown phosphorylation of alpha-synuclein at Ser129 moves the protein from the nucleus to the cytoplasm and promotes fibril formation associated with synucleinopathies (1,2,5). Recent studies also suggest that alpha-synuclein accumulation can prevent mitochondrial import machinery causing mitochondrial dysfunction that is often observed in neurodegeneration (5). It is thought that preventing alpha-synuclein aggregation may prevent PD, thus alpha-synuclein is a target for many potential therapeutic interventions aimed at decreasing aggregate formation or increasing clearance (1,2,4-6).

References

1. Villar-Pique, A., Lopes da Fonseca, T., & Outeiro, T. F. (2016). Structure, function and toxicity of alpha-synuclein: the Bermuda triangle in synucleinopathies. Journal of neurochemistry. https://doi.org/10.1111/jnc.13249

2. Emamzadeh F. N. (2016). Alpha-synuclein structure, functions, and interactions. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences. https://doi.org/10.4103/1735-1995.181989

3. Burre J. (2015). The Synaptic Function of alpha-Synuclein. Journal of Parkinson's disease. https://doi.org/10.3233/JPD-150642

4. Lashuel, H. A., Overk, C. R., Oueslati, A., & Masliah, E. (2013). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nature reviews. Neuroscience. https://doi.org/10.1038/nrn3406

5. Rocha, E. M., De Miranda, B., & Sanders, L. H. (2018). Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson's disease. Neurobiology of disease. https://doi.org/10.1016/j.nbd.2017.04.004

6. O'Leary, E. I., & Lee, J. C. (2019). Interplay between alpha-synuclein amyloid formation and membrane structure. Biochimica et biophysica acta. Proteins and proteomics. https://doi.org/10.1016/j.bbapap.2018.09.012

Alternate Names

NACP, PARK1, PARK4, SNCA, Synuclein-alpha

Entrez Gene IDs

6622 (Human)

Gene Symbol

SNCA

UniProt

P37840

Additional alpha-Synuclein Products

Product Documents for alpha-Synuclein Antibody (5C2) - BSA Free

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for alpha-Synuclein Antibody (5C2) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.